Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Choroidal Thickness Measurements During Central Serous Chorioretinopathy (CSCR) Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01610804
Recruitment Status : Completed
First Posted : June 4, 2012
Last Update Posted : June 4, 2012
Sponsor:
Information provided by (Responsible Party):
Caroline Brandl, University Hospital Regensburg

Brief Summary:

The purpose of this study is to determine changes in choroidal thickness in patients with Central Serous Chorioretinopathy (CSCR) during the first 3 months after initial diagnosis via Enhanced-Depth-Imaging-Spectral-Domain-Optical-Coherence-Tomography (EDI-OCT).

Study hypothesis: Since exudative changes in the choroid seem to constitute the primary pathology of CSCR, changes in choroidal thickness compared to healthy eyes should be present and be visible using EDI-OCT.


Condition or disease
Choroidal Thickness

Layout table for study information
Study Type : Observational
Actual Enrollment : 18 participants
Time Perspective: Prospective
Official Title: Choroidal Thickness Measurements During CSCR Treatment Applying EDI-OCT Technology
Study Start Date : April 2011
Actual Primary Completion Date : November 2011
Actual Study Completion Date : May 2012

Resource links provided by the National Library of Medicine


Group/Cohort
CSCR-Patients
Patients suffering from Central Serous Chorioretinopathy
Healthy Subjects
Healthy subjects with (assumed) normal choroidal thickness




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Patients with reduction of vision due to Central Serous Chorioretinopathy
Criteria

Inclusion Criteria:

  • Patients with initial diagnosis of CSCR and no treatment so far

Exclusion Criteria:

  • Therapy (drugs/laser) due to CSCR

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01610804


Locations
Layout table for location information
Germany
University Hospital Regensburg
Regensburg, Bavaria, Germany, 93053
Sponsors and Collaborators
University Hospital Regensburg
Investigators
Layout table for investigator information
Study Chair: Maria A Gamulescu, PD Dr. med. University Hospital Regensburg
Publications:
Layout table for additonal information
Responsible Party: Caroline Brandl, MD, University Hospital Regensburg
ClinicalTrials.gov Identifier: NCT01610804    
Other Study ID Numbers: CSCR2011
First Posted: June 4, 2012    Key Record Dates
Last Update Posted: June 4, 2012
Last Verified: May 2012